Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Eledon Pharmaceuticals ( (ELDN) ) has issued an announcement.
On November 6, 2025, Eledon Pharmaceuticals announced the results of its Phase 2 BESTOW trial, which evaluated tegoprubart for preventing organ rejection in kidney transplant patients. The trial demonstrated that tegoprubart maintains strong kidney function and reduces toxicities associated with tacrolimus, supporting its advancement to Phase 3 development. The results were presented at the American Society of Nephrology’s Kidney Week 2025, highlighting tegoprubart’s potential as a safer alternative to traditional immunosuppression regimens, with implications for improving patient outcomes and quality of life.
The most recent analyst rating on (ELDN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Eledon Pharmaceuticals stock, see the ELDN Stock Forecast page.
Spark’s Take on ELDN Stock
According to Spark, TipRanks’ AI Analyst, ELDN is a Underperform.
Eldon Pharmaceuticals faces significant financial challenges with a lack of revenue and persistent losses, reflected in its low financial performance score. The stock’s technical indicators point towards a bearish trend, further compounded by a negative P/E ratio and no dividend yield. The company’s future hinges on successful product development or strategic financial interventions to improve its financial and market position.
To see Spark’s full report on ELDN stock, click here.
More about Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions. Its lead investigational product, tegoprubart, is an anti-CD40L antibody targeting the CD40 Ligand, which plays a crucial role in immune cell activation. The company is leveraging its expertise in anti-CD40 Ligand biology to conduct studies in kidney transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is based in Irvine, California.
Average Trading Volume: 1,185,367
Technical Sentiment Signal: Buy
Current Market Cap: $241.3M
See more insights into ELDN stock on TipRanks’ Stock Analysis page.